

INDEX

Note: Page numbers in *italics* refer to Figures, those in **bold** refer to Tables.

- 5q– syndrome (myelodysplastic syndrome with isolated del(5q)) 249–250
- aceto-zinc fixative method, trephine biopsy 701
- acquired angio-oedema associated with plasma cell neoplasia 528–529
- bone marrow cytology 529
- peripheral blood 529
- acquired thrombocytopenias 575–578
- bone marrow cytology 576–577
- bone marrow histology 577
- Castelman–Kojima syndrome 575
- peripheral blood 576
- problems and pitfalls 577–578
- acute basophilic leukaemia 218, 220, 221
- acute leukaemias of ambiguous lineage 230, **231**
- acute mast cell leukaemia 315–316
- bone marrow cytology 315–316
- bone marrow histology 316
- cytochemistry 316
- peripheral blood 315
- acute megakaryoblastic leukaemia 218, 220, 221–222, 224
- acute monoblastic and monocytic leukaemia 216–217
- acute myeloid leukaemia (AML) 85, 185–230
- acute basophilic leukaemia 218, 220, 221
- acute megakaryoblastic leukaemia 218, 220, 221–222, 224
- acute monoblastic and monocytic leukaemia 216–217
- acute myelomonocytic leukaemia 216
- acute panmyelosis with myelofibrosis 219–220, 221–224
- AML not otherwise specified 213–220
- biallelic *CEBPA* mutation 208
- bone marrow histology 189–190
- classification 185–188
- cytochemistry 186–188
- cytogenetic abnormalities, recurrent 197–208
- cytogenetic analysis 190
- diagnosis **188**, **190**
- Down syndrome, myeloid proliferations related to 220–222
- erythroid leukaemia, pure 217–218, 219
- FAB (French–American–British) classification 185–186, **187**, 190–196
- flow cytometric immunophenotyping 188–189, 226
- immunohistochemistry 190
- inv(3)(q21.3q26.2) or t(3;3) (q21.3;q26.2); *GATA2*, *MECOM* 204–205
- inv(16)(p13.1q22) or t(16;16) (p13.1;q22); *CBFB*–*MYH11* 198–200
- M0 AML 190
- M1 and M2 AML 191–192, **192**, **193**
- M3 and M3 variant AML 192
- M4 AML 192, **194**
- M5 AML 192–193, **194**
- M6 AML 85, **193**, **195**–**196**
- M7 AML 193–196, **197**
- maturational, with 214–216
- maturational, without 214, 215
- minimal differentiation 213–214
- molecular genetic analysis 190
- monoclonal antibodies **188**, **190**
- myelodysplasia-related changes 208–211
- myeloid leukaemia associated with Down syndrome 221–222
- myeloid proliferations related to Down syndrome 220–222
- NPM1* mutation 207–208
- polyclonal antibodies **190**
- problems and pitfalls 229–230
- pure erythroid leukaemia 217–218, 219
- RUNX1* mutation 208
- t(1;22)(p13.3;q13.1); *RBM15*–*MKL1* 205–206
- t(6;9)(p23;q34.1); *DEK*–*NUP214* 204
- t(8;21)(q22;q22.1); *RUNX1*–*RUNX1T1* 197–198
- t(9;11)(p21.3;q23.3); *KMT2A*–*MLLT3* 203
- t(9;22)(q34.1;q11.2); *BCR*–*ABL1* 206–207
- t(15;17)(q22;q11-12); *PML*–*RARA* 200–203
- therapy-related myeloid neoplasms 211–213
- transient abnormal myelopoiesis 220–221, 222, 224
- WHO (World Health Organization) classification 186, **188**, 196–230

acute myelomonocytic
leukaemia 216

acute panmyelosis with myelofibrosis 219–220, 221–224

adult T-cell leukaemia/lymphoma (ATLL) 438–442

bone marrow cytology 439, 440

bone marrow histology 440–441

classification 439

clinical features 438

cytogenetic analysis 440

flow cytometric

- immunophenotyping 439–440

immunohistochemistry 440, 441

molecular genetic analysis 440

peripheral blood 438, 439

problems and pitfalls 441–442

aggressive NK-cell leukaemia 428–430

bone marrow cytology 428, 429

bone marrow histology 429

cytogenetic analysis 429

flow cytometric

- immunophenotyping 428, 429

immunohistochemistry 429

molecular genetic analysis 429

peripheral blood 428

problems and pitfalls 429–430

agranulocytosis 566

bone marrow cytology 566

bone marrow histology 566, 568

drugs implicated 568

peripheral blood 566

Albers-Schoenberg disease (osteopetrosis) 693–695

alcan blue 70

alcohol, haematological effects *see* haematological effects of alcohol

ALK-positive large B-cell lymphoma 413

alpha heavy chain disease 524

AML *see* acute myeloid leukaemia

ammonium tetrathiomolybdate, haematological effects 599

amyloid deposition, infection and reactive changes 167

anaemia of chronic disease 555–556

bone marrow cytology 555

bone marrow histology 556

peripheral blood 555

problems and pitfalls 556

anaemias

- see also* red cells disorders

anaemia of chronic disease 555–556

aplastic anaemia 602–609

congenital dyserythropoietic anaemias (CDA) 547–551

Fanconi anaemia 33, 522, 573, 603, 607, 608, 609

haemolytic anaemias 544–547

iron deficiency anaemia 537–539

megaloblastic anaemia 551–555

myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)/refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) 327–329

refractory anaemia with excess of blasts (RAEB) 247–249

refractory anaemia with ring sideroblasts (RARS) 245–246

refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T)/myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) 327–329

sideroblastic anaemia 539–541

anaplastic large cell lymphoma (ALCL), ALK-negative 449–450

cytogenetic analysis 449

flow cytometric

- immunophenotyping 449

immunohistochemistry 449

molecular genetic analysis 449

problems and pitfalls 450

anaplastic large cell lymphoma (ALCL), ALK-positive 444–449

bone marrow cytology 445–446

bone marrow histology 446–447, 448, 449

cytogenetic analysis 446, 447

flow cytometric

- immunophenotyping 446, 447

immunohistochemistry 447–448

molecular genetic analysis 446, 447

peripheral blood 445

problems and pitfalls 448–449

angioimmunoblastic T-cell lymphoma 434–438

bone marrow cytology 435

bone marrow histology 436–437

clinical features 434

cytogenetic analysis 435–436

flow cytometric

- immunophenotyping 435, 436

immunohistochemistry 436, 437–438

incidence 434

molecular genetic analysis 435–436

peripheral blood 435

problems and pitfalls 438

angiosarcoma 666, 667, 668–669, 670

HIV/AIDS 666, 667

antigens

- expressed by lymphoid cells 77–85, 80–84
- expressed by myeloid cells 77–85, 78–79
- expressed by non-haemopoietic cells, for demonstration of metastatic tumours 647–650

antimarial therapy (sodium stibogluconate), haematological effects 597

aplastic anaemia 602–609

bone marrow cytology 605–606

bone marrow histology 606–607

causes 603–604, 604, 610

classification 604–605

cytogenetic analysis 607–608

diagnosis 604

dyskeratosis congenita 603–604

Fanconi anaemia 33, 522, 573, 603, 607, 608, 609

Hoyeraal-Hreidarsson syndrome 604

hypocellular MDS 608–609, 610

immunohistochemistry 608

incidence 602–603

molecular genetic analysis 607–608

peripheral blood 605

problems and pitfalls 608–609

prognosis 604

arsenic, haematological effects 598, 599

artefacts

- aspiration biopsy 45–57
- cytology 45–48
- histology 48–57
- trephine biopsy 45–57

aspiration biopsy 6–7, 9–10, 11

artefacts 45–57

audit 45

cytochemical stains 61–64

diagnostic technique 61–64

guidelines 45

interpretation 39–43

reports 45

assessment of bone

bone marrow culture for assessment of haemopoietic progenitor cell numbers 104–105

problems and pitfalls 695–696

- atypical chronic myeloid leukaemia,
BCR-ABL1 negative 320–324
 bone marrow cytology 322, 323
 bone marrow histology 322–323
 cytogenetic analysis 323–324
 molecular genetic analysis 323–324
 peripheral blood 322
 problems and pitfalls 324
 WHO (World Health Organization)
 classification 322
- autoimmune disorders 590–591
 bone marrow aspirate 591
 bone marrow histology 591
 peripheral blood 591
 problems and pitfalls 591
 autoimmune lymphoproliferative
 syndrome 592
 bone marrow cytology 592
 bone marrow histology 592
 immunophenotyping 592
 peripheral blood 592
 problems and pitfalls 592
- autoimmune neutropenia
 567–568, 569
 bone marrow cytology 568, 569
 peripheral blood 568
- bacterial and rickettsial infection
 bone marrow cytology 111–113
 bone marrow histology 113–116
 infection and reactive changes
 109–116
 peripheral blood 109–111
 problems and pitfalls 116
 Whipple's disease 110–111, 113
- B-cell prolymphocytic leukaemia
 (B-PLL) 351, 367–370
 bone marrow cytology 368
 bone marrow histology 369–370
 cytogenetic analysis 369
 flow cytometric
 immunophenotyping 368
 immunohistochemistry 370
 molecular genetic analysis 369
 peripheral blood 368
 problems and pitfalls 370
 benzene, haematological effects 599
- Bernard–Soulier syndrome,
 congenital thrombocytopenia
 573, 574
- biallelic *CEBPA* mutation, acute
 myeloid leukaemia (AML) 208
- bisphosphonate therapy 695
- Blackfan–Diamond syndrome
 558–563
 bone marrow cytology 560, 561
- bone marrow histology
 560–562, 563
 causes 559
 peripheral blood 560
 problems and pitfalls 562–563
- blastic plasmacytoid dendritic cell
 neoplasm
 acute myeloid leukaemia (AML)
 222–229
- bone marrow cytology 225–226
 bone marrow histology 227–228
 cytochemistry 226
 cytogenetic analysis 228–229
 flow cytometric
 immunophenotyping 226
 immunohistochemistry 227–228
 molecular genetic analysis
 228–229
 peripheral blood 225
- B-lineage lymphomas and
 leukaemias 351–418
- B-cell prolymphocytic leukaemia
 (B-PLL) 367–370
- B-lymphoblastic leukaemia/
 lymphoma 351–367
- Burkitt lymphoma 413–418
- diffuse large B-cell lymphoma,
 not otherwise specified
 401–407
- diffuse large B-cell lymphoma and
 other large B-cell and high grade
 B-cell lymphomas 401
- extranodal marginal zone
 lymphoma of mucosa-associated
 lymphoid tissue (MALT
 lymphoma) 392–393
- follicular lymphoma 380–387
- hair cell leukaemia 370–375
- heavy chain diseases 380
- IgM monoclonal gammopathy of
 undetermined significance 380
- lymphoplasmacytic lymphoma
 375–380
- mantle cell lymphoma 387–392
- monoclonal B-cell
 lymphocytosis 367
- nodal marginal zone B-cell
 lymphoma 398–399
- patterns 349
- splenic B-cell lymphoma/
 leukaemia, unclassifiable
 399–401
- splenic marginal zone lymphoma
 393–398
- WHO (World Health Organization)
 classification 347
- B-lymphoblastic leukaemia/
 lymphoma 351–367
- bone assessment *see* assessment of
 bone
- bone marrow culture for assessment
 of haemopoietic progenitor cell
 numbers, diagnostic technique
 104–105
- bone marrow culture for
 microorganisms, diagnostic
 technique 106
- bone marrow dysplasia with
 polyclonal haemopoiesis
 585–590
- dysplasia as a feature of an
 inherited condition 585–586
 secondary myelodysplasia
 586–590
- bone marrow fibrosis 160, 162,
 168–170
- bone marrow cytology 168–170
- bone marrow histology 170
- causes 169
- infection and reactive
 changes 168–170
- peripheral blood 168
- problems and pitfalls 170
- bone marrow granulomas *see*
 granulomas
- bone marrow infiltration in
 lymphoproliferative disorders
 346–351
- detection 349–351
- immunohistochemical techniques
 350, 351
- patterns 346–349
- problems and pitfalls 350–351
- bone marrow necrosis
 bone marrow cytology 164
 bone marrow histology 164–166
 causes 163
- infection and reactive changes
 162–166
- peripheral blood 164
- problems and pitfalls 166
- bone marrow organization
 bone 1–4
 connective tissue 4–5
 haemopoietic cells 5–6
- bone necrosis (osteonecrosis) and
 repair 693
- Bouin's fixative 70–71, 699
- B-PLL *see* B-cell prolymphocytic
 leukaemia
- breast carcinoma 655, 657, 659, 663,
 664, 674

Burkitt lymphoma 413–418
 bone marrow cytology 415–416
 bone marrow histology 417, 418
 cytogenetic analysis 416–417
 flow cytometric
 immunophenotyping 416
 immunohistochemistry 417–418
 molecular genetic analysis
 416–417
 peripheral blood 415
 problems and pitfalls 418

cancer, non-metastatic effects 585, 586

carcinoïd tumour 654, 665

Castelman–Kojima syndrome,
 acquired thrombocytopenias 575

CDA *see* congenital dyserythropoietic anaemias

CEL *see* chronic eosinophilic leukaemia

cellular composition of bone marrow 36–39
 cytology 36–38
 histology 38–39

cellularity 10–13
 neonates 11–12
 variability 12–13

CHAD *see* chronic cold haemagglutinin disease

Chagas disease 132, 133, 135, 136

Chédiak–Higashi syndrome 571–573
 bone marrow cytology 571–573
 bone marrow histology 573
 peripheral blood 571

chemotherapy, haematological effects
see haematological effects of anti-cancer and immunosuppressive chemotherapy

chloramphenicol, haematological effects 597

chloroacetate esterase (Leder's stain) 70

chronic cold haemagglutinin disease (CHAD) 524
 bone marrow cytology 524
 bone marrow histology 524
 cytogenetic analysis 524
 flow cytometric
 immunophenotyping 524
 immunohistochemistry 524
 molecular genetic analysis 524
 peripheral blood 524

chronic eosinophilic leukaemia (CEL), not otherwise specified 299–302
 bone marrow cytology 301
 bone marrow histology 301, 302
 cytogenetic analysis 301
 diagnostic pathway 303
 molecular genetic analysis 301
 peripheral blood 301
 problems and pitfalls 300, 301–302
 WHO (World Health Organization)
 classification 300

chronic idiopathic myelofibrosis *see* primary myelofibrosis

chronic lymphoproliferative disorder of NK lineage 427–428

chronic myeloid leukaemia (CML),
BCR-ABL1+ (chronic
 myelogenous leukaemia, chronic granulocytic leukaemia) 268–277
 bone marrow cytology 270–271
 bone marrow histology 271–275
 cytogenetic analysis 275
 diagnosis 269
 molecular genetic analysis 275
 peripheral blood 269–270
 problems and pitfalls 276–277
 WHO (World Health Organization)
 classification 269

chronic myelomonocytic leukaemia (CMML) 317–320
 bone marrow cytology 318
 bone marrow histology 318–319, 321
 cytogenetic analysis 319–320
 immunophenotyping 319
 molecular genetic analysis 319–320
 peripheral blood 318
 problems and pitfalls 320
 WHO (World Health Organization)
 classification 318

chronic neutrophilic leukaemia 277–279
 bone marrow cytology 277, 278
 bone marrow histology 278
 cytogenetic analysis 278
 molecular genetic analysis 278
 peripheral blood 277, 278
 problems and pitfalls 278–279

classic Hodgkin lymphoma *see* Hodgkin's disease

clonal immunoglobulin rearrangements, molecular genetic analysis 102–103

CML *see* chronic myeloid leukaemia

CMM^L *see* chronic myelomonocytic leukaemia

cocaine abuse, haematological effects 597

colchicine toxicity, haematological effects 597

collagen stains 67–70

congenital dyserythropoietic anaemias (CDA) 547–551
 bone marrow cytology 548
 bone marrow histology 548, 549–550, 551

clinical features 547

diagnostic features 547
 peripheral blood 547, 548
 problems and pitfalls 548–551

congenital immune deficiency syndromes 591–592
 bone marrow cytology 592
 bone marrow histology 592
 immunophenotyping 592
 peripheral blood 592

congenital neutropenia 563–565
 bone marrow cytology 564–565
 bone marrow histology 564–565
 cytogenetic analysis 566
 molecular genetic analysis 566
 peripheral blood 564

Shwachman–Diamond syndrome 564

congenital thrombocytopenias 573–575
 Bernard–Soulier syndrome 573, 574
 bone marrow cytology 574–575
 bone marrow histology 575
 May–Hegglin anomaly 573, 574
 peripheral blood 573–574
 Wiskott–Aldrich syndrome 573, 574

Congo red stain 70

connective tissue, bone marrow organization 4–5

connective tissue disorders 590–591
 bone marrow aspirate 591
 bone marrow histology 591
 peripheral blood 591
 problems and pitfalls 591

copper deficiency, haematological effects 599, 600

crystal-containing macrophages in myeloid leukaemias 629
 bone marrow cytology 629
 bone marrow histology 629
 peripheral blood 629

- crystal-storing histiocytosis 624–625
 cystinosis 629–630, 631
 bone marrow cytology 629
 bone marrow histology 629–630, 631
 peripheral blood 629
 cytochemical stains
 aspiration biopsy 61–64
 diagnostic techniques 61–64, **70**
 Perls' stain for haemosiderin 36, 61–63
 cytogenetic abnormalities, recurrent, acute myeloid leukaemia (AML) 197–208
 cytokeratin 7 (CK7), cytokeratin 20 (CK20) and other markers, metastatic tumours **651**, 657
 cytokine effects *see* haemopoietic growth factors
 cytological abnormalities in plasma cells, infection and reactive changes 147–149
 cytology
 artefacts 45–48
 cellular composition of bone marrow 36–38
 erythroblast iron 36
 erythropoiesis 13–16
 fat cells 33, 35
 granulopoiesis 19–20
 lymphocytes 34–35
 mast cells 28, 30
 monocytopenia 21
 osteoblasts 31, 32
 osteoclasts 31, 32
 plasma cells 35–36
 stromal dendritic cells 23
 cytomegalovirus (CMV) 119, 123
 diagnosis **124**
 decalcification, trephine biopsy 700, 701
 dendritic cell neoplasms *see* histiocytic and dendritic cell neoplasms
 diagnostic techniques 61–106
 aspiration biopsy 61–64
 bone marrow culture for assessment of haemopoietic progenitor cell numbers 104–105
 bone marrow culture for microorganisms 106
 cytochemical stains 61–64, **70**
 cytogenetic analysis 89–91
 haemopoietic progenitor cell numbers assessment 104–105
 histochemical stains 65–71
 immunophenotyping 71–89
 long-term haemopoietic cultures 105
 molecular genetic analysis 91–104
 short-term haemopoietic cultures 104–105
 trephine biopsy 65–71
 ultrastructural examination 104
 diffuse large B-cell lymphoma, not otherwise specified 401–407
 bone marrow cytology 402–403
 bone marrow histology 403–405
 cytogenetic analysis 405–406
 flow cytometric
 immunophenotyping 405
 immunohistochemistry 405, 406–407
 molecular genetic analysis 405–406
 405–406
 peripheral blood 402
 problems and pitfalls 407
 diffuse large B-cell lymphoma and other large B-cell and high grade B-cell lymphomas (DLBCL) 401–413
 disseminated juvenile xanthogranuloma 260
 DLBCL *see* diffuse large B-cell lymphoma and other large B-cell and high grade B-cell lymphomas
 donor-lymphocyte infusion
 graft-versus-host disease (GVHD) 617
 stem cell transplantation 617
 Down syndrome, myeloid proliferations, acute myeloid leukaemia (AML) 220–222
 donor-lymphocyte infusion
 graft-versus-host disease (GVHD) 617
 stem cell transplantation 617
 Down syndrome, myeloid proliferations, acute myeloid leukaemia (AML) 220–222
 donor-lymphocyte infusion
 graft-versus-host disease (GVHD) 617
 stem cell transplantation 617
 dyskeratosis congenita 603–604
 dysplasia *see* bone marrow dysplasia with polyclonal haemopoiesis
 endochondrial ossification 3–4
 enteropathy-associated T-cell lymphoma 450
 Epstein–Barr virus (EBV)
 diagnosis **124**
 EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood 430
 post-transplant and other immunodeficiency-associated lymphoproliferative disorders and their relationship to the Epstein–Barr virus 460–464
 Erdheim–Chester disease 260
 erythroblast iron 36
 erythroid islands 14–18
 erythroid leukaemia, pure, acute myeloid leukaemia (AML) 217–218, 219
 erythropoiesis 13–18
 cytology 13–16
 histology 16–18
 essential and other paraprotein-associated cryoglobulinaemia 522–524
 bone marrow cytology 523–524
 bone marrow histology 523–524
 cytogenetic analysis 524
 molecular genetic analysis 524
 peripheral blood 523
 essential thrombocythaemia (ET) 284–291
 bone marrow cytology 286
 bone marrow histology 286–288
 cytogenetic analysis 288–289
 molecular genetic analysis 288–289
 peripheral blood 285–286
 problems and pitfalls 289–291
 splenomegaly 285
 thrombocytosis 284–285
 WHO (World Health Organization) classification 285
 Ewing's sarcoma 448, 672
 bone marrow cytology 652
 cytogenetic analysis 656, **657**
 molecular genetic analysis 657, 658
 examination, bone marrow 6–10
 aspiration biopsy 6–7, 9–10, 11, 39–43
 metastatic tumours 675–678
 trephine biopsy 7–10, 13, 23, 24, 43–45
 ultrastructural examination 104
 extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 392–393
 bone marrow cytology 393, 394, 395
 bone marrow histology 393, 394, 395
 cytogenetic analysis 393
 flow cytometric
 immunophenotyping 393
 immunohistochemistry 393
 molecular genetic analysis 393
 peripheral blood 393
 problems and pitfalls 393

- extranodal NK/T-cell lymphoma,
nasal type 430–431
bone marrow cytology 431
bone marrow histology 431
cytogenetic analysis 431
flow cytometric
immunophenotyping 431
immunohistochemistry 431
molecular genetic analysis 431
peripheral blood 430–431
problems and pitfalls 431
- FAB (French–American–British)
classification
acute myeloid leukaemia (AML)
185–186, **187**, 190–196
myelodysplastic syndromes
(MDS) **232**
falciparum malaria 133, 134
familial lymphohistiocytosis 150,
153, **154**, 156
familial thrombocytosis 576–578
bone marrow cytology 578
bone marrow histology 578
peripheral blood 578
problems and pitfalls 578
Fanconi anaemia 33, 522, 573, 603,
607, 608, 609
fat cells 33–34
fibrosis, bone marrow 160, 162,
168–170
infection and reactive changes
168–170
fibrous dysplasia of bone including
McCune–Albright syndrome 695
- FICTION (fluorescence
immunophenotyping and
interphase cytogenetics) 95
- filariasis 134
- FISH *see* fluorescence *in situ*
hybridization
- fixation, trephine biopsy 699–700, 701
- flow cytometric immunophenotyping
71–73, **74–75**, **76**
principle 72
problems and pitfalls 72–73
- fluorescence immunophenotyping
and interphase cytogenetics
(FICTION) 95
- fluorescence *in situ* hybridization
(FISH) 91–97
principles 93–94
spectral karyotyping (SKY) 95–96
- foamy macrophages 139, 142
causes 626–628
- Erdheim–Chester disease 260
- Niemann–Pick disease 625
sickle cell disease 556, 557
storage diseases and storage cells in
the bone marrow 626–628
Zieve's syndrome 602, 603
- follicular lymphoma 380–387
bone marrow cytology 381–382
bone marrow histology 383–386
cytogenetic analysis 383
definition 380
flow cytometric
immunophenotyping 382, 383
immunohistochemistry 383,
386–387
incidence 381
molecular genetic analysis 383
peripheral blood 381, 382
primary cutaneous follicle centre
cell lymphoma 387
problems and pitfalls 387
in situ follicular neoplasia 387
transformations 381
variants 387
- foreign substances deposition
633–634
- fungal infections
bone marrow cytology 126–128
bone marrow histology 128–130
differential diagnosis **131**
HIV/AIDS 126, 127–130
infection and reactive changes
126–131
peripheral blood 126
problems and pitfalls 130–131
- fusion genes, leukaemia/
lymphoma-associated 103–104
- gamma heavy chain disease 524–525
bone marrow cytology 525
bone marrow histology 525
peripheral blood 525
- Gaucher's disease 622–623
bone marrow cytology 622–623
bone marrow histology 623
peripheral blood 622
- gelatinous transformation
bone marrow cytology 166
bone marrow histology 166–167
infection and reactive changes
166–167
peripheral blood 166
- Giemsa staining
paraffin-embedded trephine biopsy
sections 702
- resin-embedded trephine biopsy
sections 705–706
- glycogen storage disease 633
glycol methacrylate (resin
embedding), trephine biopsy 701
- GMS (Grocott's methenamine silver)
stain **70**
- Gomori's method for reticulin
staining, trephine biopsy
703–704
- Gordon and Sweet's technique for
reticulin staining, trephine
biopsy 702–703
- Gorham's disease 695
- gout 633
- graft-versus-host disease (GVHD)
bone marrow cytology 617
bone marrow histology 617
donor-lymphocyte infusion 617
peripheral blood 617
stem cell transplantation 614–617
- granulomas 136–145, **137–138**
bone marrow cytology 138
bone marrow histology 138–144
disseminated juvenile
xanthogranuloma 260
HIV/AIDS 141
infection and reactive changes
136–145
juvenile xanthogranuloma 260
lipid granulomas 138–139
peripheral blood 137
problems and pitfalls 144–145
- granulopoiesis 14, 19–21
cytology 19–20
histology 20–21
- Grocott's methenamine silver (GMS)
stain **70**
- GVHD *see* graft-versus-host disease
- H&E *see* haematoxylin and eosin
- haemangiolympangioma 668, 673
- haematological effects of
alcohol 601–602
bone marrow cytology 602, 603
bone marrow histology 602
peripheral blood 601–602
problems and pitfalls 602
Zieve's syndrome 602, 603
- haematological effects of anti-cancer
and immunosuppressive
chemotherapy 592–597
- bone marrow cytology
593–595, 596
- bone marrow histology
595–596, 597
- peripheral blood 593, 594
problems and pitfalls 597

- haematological effects of other drugs
and chemicals 597–599, 600
- haematoxylin and eosin (H&E)
paraffin-embedded trephine biopsy
sections 702
- resin-embedded trephine biopsy
sections 705
- haemoglobin H disease 544
- bone marrow cytology 544, 545
- bone marrow histology 544
- peripheral blood 544
- problems and pitfalls 544
- haemolytic anaemias 544–547
- bone marrow cytology 545–546
- bone marrow histology 546
- peripheral blood 544–545
- problems and pitfalls 547
- haemophagocytic syndromes 150–158
- bone marrow cytology 154–155
- bone marrow histology 155–158
- conditions associated with 150–154
- immunohistochemistry 158
- infection and reactive changes 150–158
- peripheral blood 154
- problems and pitfalls 158
- haemopoiesis, constitutional abnormalities 610–611, 612
- haemopoietic cells, bone marrow organization 5–6
- haemopoietic growth factors 617–620
- bone marrow cytology 618, 619
- bone marrow histology 619–620
- effects 617–620
- peripheral blood 618
- problems and pitfalls 620
- haemopoietic marrow, distribution 1
- haemopoietic progenitor cell numbers assessment, diagnostic technique 104–105
- hairy cell leukaemia 370–375
- bone marrow cytology 370, 371
- bone marrow histology 372–374
- cytogenetic analysis 371, 372
- flow cytometric immunophenotyping 371
- immunohistochemistry 371, 374
- molecular genetic analysis 371, 372
- peripheral blood 370, 371
- problems and pitfalls 375
- hairy cell leukaemia variant 400–401
- bone marrow cytology 400
- bone marrow histology 401
- cytogenetic analysis 401
- flow cytometric immunophenotyping 401
- molecular genetic analysis 401
- peripheral blood 400
- heavy chain diseases 375, 380, 392, 454, 521–522
- alpha heavy chain disease 524
- B-lineage lymphomas and leukaemias 380
- gamma heavy chain disease 524–525
- mu heavy chain disease 525
- hepatitis C infection 126
- hepatosplenic T-cell lymphoma 442–444
- bone marrow cytology 442, 443
- bone marrow histology 443, 444
- cytogenetic analysis 442–443
- flow cytometric immunophenotyping 442, 443
- immunohistochemistry 443–444
- molecular genetic analysis 442–443
- peripheral blood 442
- problems and pitfalls 444
- herpes simplex, diagnosis 124
- HHV8 *see* human herpesvirus 8
- high grade B-cell lymphoma with *MYC* and *BCL2* and/or *BCL6* rearrangements 413, 414, 415
- histiocytic and dendritic cell neoplasms 253–260
- disseminated juvenile xanthogranuloma 260
- Erdheim–Chester disease 260
- histiocytic sarcoma (including malignant histiocytosis) 253–256
- interdigitating dendritic cell sarcoma 260
- juvenile xanthogranuloma 260
- Langerhans cell histiocytosis 256–260
- histiocytic sarcoma (including malignant histiocytosis) 253–256
- bone marrow cytology 254–255
- bone marrow histology 255–256
- cytogenetic analysis 256
- immunohistochemistry 256
- molecular genetic analysis 256
- peripheral blood 254
- problems and pitfalls 256, 257
- histiocytosis, infection and reactive changes 149–150
- histochemical staining 65–71
- collagen stains 67–70
- diagnostic techniques 65–71
- paraffin-embedded trephine biopsy sections 701–705, 706–707
- Perls' stain for haemosiderin 65–67
- resin-embedded trephine biopsy sections 705–706
- reticulin staining 67–70
- trephine biopsy 65–71, 701–707
- histology artefacts 48–57
- cellular composition of bone marrow 38–39
- erythroblast iron 36
- erythropoiesis 16–18
- fat cells 34
- granulopoiesis 20–21
- lymphocytes 35
- mast cells 28–29, 30–31
- monocytopoiesis 21–22
- osteoblasts 32, 33, 34
- osteoclasts 32, 33, 34
- plasma cells 36, 37
- stromal dendritic cells 23
- HIV/AIDS 112, 115, 159–162
- bone marrow cytology 160
- bone marrow histology 160–162
- diagnosis 124
- fungal infections 126, 127–130
- human herpesvirus 8 (HHV8)-associated multicentric Castleman's disease 162
- infection and reactive changes 159–162
- Kaposi's sarcoma 162, 666, 667, 673
- non-Hodgkin lymphoma 162
- opportunistic infections 160–162
- peripheral blood 159
- plasma cell myeloma (multiple myeloma) 506, 508
- polymorphous lymphoid aggregate 161
- Hodgkin lymphoma 13, 453–459
- genotypic and phenotypic features of the neoplastic cells 453
- WHO (World Health Organization) classification 348
- bone marrow cytology 455
- bone marrow histology 456–458
- cytogenetic analysis 456, 459
- diagnosis 454–455
- flow cytometric immunophenotyping 456, 459

- Hodgkin lymphoma (*cont'd*)
 immunohistochemistry 458–459
 incidence 454
 molecular genetic analysis 456, 459
 peripheral blood 455
 problems and pitfalls 459
 Reed–Sternberg cells 454
 Hodgkin's disease (classic Hodgkin lymphoma) *see* Hodgkin lymphoma
 Hoyeraal–Hreidarsson syndrome 604
 human herpesvirus 6 infection 121
 human herpesvirus 8 (HHV8), diagnosis 124
 human herpesvirus 8 (HHV8)-associated multicentric Castleman's disease 122, 123
 HIV/AIDS 162
 hyperoxaluria 630–631, 632
 bone marrow biopsy 631, 632
 peripheral blood 630
 hyperparathyroidism 687–688
 causes 687–688
 paratrabecular fibrosis 688
 hypervitaminosis A, haematological effects 599
 hypocellular MDS, aplastic anaemia 608–609, 610
- idiopathic hypereosinophilic syndrome 569–571
 bone marrow cytology 570
 bone marrow histology 570–571
 diagnosis 569
 peripheral blood 569–570
 problems and pitfalls 571
 IgM monoclonal gammopathy of undetermined significance (IgM MGUS) 380, 514
- immunocytochemistry 73–75, 76
 immunofluorescence flow cytometry *see* flow cytometric immunophenotyping
 immunohistochemical staining of paraffin-embedded sections, trephine biopsy 706–707
 immunohistochemical techniques, bone marrow infiltration in lymphoproliferative disorders 350, 351
 immunohistochemistry acute myeloid leukaemia (AML) 190
 antigens expressed by lymphoid cells **80–84**
- antigens expressed by myeloid cells **78–79**
 B-cell prolymphocytic leukaemia (B-PLL) 370
 blastic plasmacytoid dendritic cell neoplasm 227–228
 diffuse large B-cell lymphoma, not otherwise specified 405, 406–407
 extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) 393
 follicular lymphoma 383, 386–387
 haemophagocytic syndromes 158
 hairy cell leukaemia 371, 374
 histiocytic sarcoma (including malignant histiocytosis) 256
 immunophenotyping 75–89
 intravascular large B-cell lymphoma 411
 Langerhans cell histiocytosis 257
 lymphoplasmacytic lymphoma 377, 380
 mantle cell lymphoma 390, 392
 nodal marginal zone B-cell lymphoma 399
 splenic marginal zone lymphoma (SMZL) 396, 398
 stromal dendritic cells 23–24
 T-cell/histiocyte-rich large B-cell lymphoma 408, 409
 trephine biopsy 85–88
 immunophenotyping 71–89
 diagnostic technique 71–89
 flow cytometric immunophenotyping 71–73, 74–75, 76
 immunocytochemistry 73–75, 76
 immunohistochemistry 75–89
 immunoproliferative small intestinal disease (IPSID) 524
 immunosuppressive chemotherapy, haematological effects *see* haematological effects of anti-cancer and immunosuppressive chemotherapy
 infection and reactive changes 109–170
 amyloid deposition 167
 bacterial and rickettsial infection 109–116
 bone marrow fibrosis 168–170
 bone marrow granulomas 136–145
 bone marrow necrosis 162–166
- cytological abnormalities in plasma cells 147–149
 fibrosis, bone marrow 168–170
 fungal infections 126–131
 gelatinous transformation 166–167
 haemophagocytic syndromes 150–158
 histiocytosis 149–150
 HIV/AIDS 159–162
 iron overload 158–159
 mast cells 149
 parasitic diseases 131–136
 plasmacytosis 147–149
 polymorphous lymphoid hyperplasia 145–147
 reactive lymphoid aggregates 145–147
 rickettsial and bacterial infection 109–116
 serous degeneration/atrophy 166–167
 viral infections 116–126
 infectious mononucleosis 119, 120, 121, 125
in situ follicular neoplasia, follicular lymphoma 387
in situ hybridization (ISH) 91–97
 advantages 95
 disadvantages 96
 interdigitating dendritic cell sarcoma 260
 interferon, haematological effects 597
 International Prognostic Scoring System (IPSS-R), myelodysplastic syndromes (MDS) 242, **243**
 intravascular large B-cell lymphoma 409–411
 bone marrow cytology 410–411
 bone marrow histology 411, 412
 immunohistochemistry 411, 412, 413
 peripheral blood 409–410
 inv(3)(q21.3q26.2) or t(3;3) (q21.3;q26.2); *GATA2*, *MECOM*, acute myeloid leukaemia (AML) 204–205
 inv(16)(p13.1q22) or t(16;16) (p13.1;q22); *CBFB*–*MYH11*, acute myeloid leukaemia (AML) 198–200
 IPSID (immunoproliferative small intestinal disease) 524
 IPSS-R (International Prognostic Scoring System), myelodysplastic syndromes (MDS) 242, **243**

iron, erythroblast iron 36
 iron deficiency anaemia 537–539
 bone marrow cytology 537–538
 bone marrow histology 538
 peripheral blood 537
 problems and pitfalls 538–539
 iron overload
 bone marrow cytology 159
 bone marrow histology 159
 infection and reactive changes
 158–159
 peripheral blood 159
 irradiation effect on bone marrow
 599–602
 bone marrow cytology 599
 bone marrow histology 599–601
 peripheral blood 599
 ISH *see in situ* hybridization
 isoniazid, haematological effects 597
 JMML *see* juvenile myelomonocytic leukaemia
 Jordans anomaly 565–566
 bone marrow cytology 566
 peripheral blood 566
 juvenile myelomonocytic leukaemia (JMML) 324–327
 bone marrow cytology 324, 327
 bone marrow histology 324
 peripheral blood 324, 326
 problems and pitfalls 326–327
 WHO (World Health Organization) classification 325
 juvenile xanthogranuloma 260
 Kaposi's sarcoma 666, 667, 668–669
 HIV/AIDS 162, 666, 667, 673
 kidney carcinoma 653
 Kostmann syndrome 563
 kwashiorkor 621–622
 Langerhans cell histiocytosis 256–260
 bone marrow cytology 256
 bone marrow histology 256
 cytogenetic analysis 257–258
 immunohistochemistry 257
 immunophenotype 256
 molecular genetic analysis 257–258
 peripheral blood 256
 problems and pitfalls 258–260
 large B-cell lymphoma arising in HHV8-associated multicentric Castleman's disease 411
 lead poisoning, haematological effects 598

Leder's stain (chloroacetate esterase) 70
 leishmaniasis 6, 131–132
 lepromatous leprosy 110, 112, 113
 leucocytes disorders 563–573
 agranulocytosis 566
 autoimmune neutropenia 567–568, 569
 Chédiak–Higashi syndrome 571–573
 congenital neutropenia 563–565
 idiopathic hypereosinophilic syndrome 569–571
 Jordans anomaly 565–566
 Kostmann syndrome 563
 neutropenia, drug-induced 566–567
 Pelger–Huët anomaly 566, 567, 593
 leukaemia investigation, molecular genetic analysis 102
 leukaemia/lymphoma-associated fusion genes, molecular genetic analysis 103–104
 light chain and heavy chain deposition diseases 521–522
 bone marrow cytology 522
 peripheral blood 522
 WHO (World Health Organization) classification 522
 light chain-associated amyloidosis 518–521
 bone marrow cytology 518–519
 bone marrow histology 519, 520–521
 classification 518
 cytogenetic analysis 519
 immunohistochemistry 519
 molecular genetic analysis 519
 peripheral blood 518
 problems and pitfalls 519–521
 WHO (World Health Organization) classification 518
 linezolid, haematological effects 597
 lipid granulomas 138–139
 long-term haemopoietic cultures, diagnostic technique 105
 lung carcinoma 656, 662–665, 664
 lymphocytes
 cytology 34–35
 histology 35
 lymphopoiesis 34–35
 lymphoma investigation, molecular genetic analysis 102
 lymphoma/leukaemia-associated fusion genes, molecular genetic analysis 103–104
 lymphoplasmacytic lymphoma 375–380
 bone marrow cytology 376
 bone marrow histology 377–379
 cytogenetic analysis 376–377
 flow cytometric immunophenotyping 376, 377
 immunohistochemistry 377, 380
 molecular genetic analysis 376–377
 peripheral blood 376
 problems and pitfalls 380
 lymphopoiesis 34–36
 lymphocytes 34–35
 plasma cells 35–36
 lymphoproliferative disorders 346–464
 B-lineage lymphomas and leukaemias 351–418
 bone marrow infiltration 346–351
 lymphoproliferative disorders of T lineage and natural killer (NK) lineage 418–464
 adult T-cell leukaemia/lymphoma (ATLL) 438–442
 aggressive NK-cell leukaemia 428–430
 anaplastic large cell lymphoma (ALCL), ALK-negative 449–450
 anaplastic large cell lymphoma (ALCL), ALK-positive 444–449
 angioimmunoblastic T-cell lymphoma 433–438
 chronic lymphoproliferative disorder of NK lineage 427–428
 diagnosis 418–419
 enteropathy-associated T-cell lymphoma 450
 Epstein–Barr virus (EBV)-positive T-cell and NK-cell lymphoproliferative diseases of childhood 430
 extranodal NK/T-cell lymphoma, nasal type 430–431
 hepatosplenitic T-cell lymphoma 442–444
 mycosis fungoides 434
 NK-lymphoblastic leukaemia/lymphoma 421
 peripheral T-cell lymphoma, not otherwise specified 450–453
 post-transplant and other immunodeficiency-associated lymphoproliferative disorders and their relationship to the Epstein–Barr virus 460–464

- lymphoproliferative disorders of T lineage and natural killer (NK) lineage (*cont'd*)
 primary cutaneous gamma-delta T-cell lymphoma 433
 Sézary syndrome 431–433
 subcutaneous panniculitis-like T-cell lymphoma 434
 T-cell large granular lymphocytic leukaemia 424–427
 T-cell prolymphocytic leukaemia 422–424
 T-lymphoblastic leukaemia/lymphoma 419–421
 WHO (World Health Organization) classification 418–419
- macrophages containing cholesterol crystals 628
- malignant cells of non-haemopoietic origin, metastatic tumours 679–680
- malignant melanoma 653, 665, 666, 673
- Kaposi's sarcoma 673
- MALT lymphoma *see* extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
- mantle cell lymphoma 387–392
 bone marrow cytology 389
 bone marrow histology 390–392
 cytogenetic analysis 390
 flow cytometric immunophenotyping 389–390
 immunohistochemistry 390, 392
 incidence 388
 molecular genetic analysis 390
 peripheral blood 388–389
 problems and pitfalls 392
- marasmus 621–622
- marrow fat 5
- Martius scarlet blue (MSB) 70
- mast cells 28–31
 bone marrow cytology 149
 bone marrow histology 149
 cytology 28, 30
 histology 28–29, 30–31
 infection and reactive changes 149
 peripheral blood 149
 problems and pitfalls 149
- mastocytosis *see* systemic mastocytosis
- May-Hegglin anomaly, congenital thrombocytopenia 573, 574
- McCune-Albright syndrome 695
- MDS *see* myelodysplastic syndromes
- MDS-EB *see* myelodysplastic syndrome with excess blasts
- MDS-RS-SLD *see* myelodysplastic syndrome with single lineage dysplasia and ring sideroblasts
- megakaryopoiesis 24–28
 cytology 24–27
 histology 27–28
- megaloblastic anaemia 551–555
 bone marrow cytology 552–553
 bone marrow histology 553, 554
 causes 551
 peripheral blood 551–552
 problems and pitfalls 553–555
- metastatic tumours 645–680
 angiosarcoma 162, 666, 667, 668–669, 670
 antigens expressed by non-haemopoietic cells 647–650
 bone marrow cytology 651–656
 bone marrow examination, identifying the tissue of origin of metastases and markers of relevance to prognosis or treatment 678
- bone marrow examination, staging of solid tumours 675–678
- bone marrow histology 658–668
- breast carcinoma 655, 657, 659, 663, 664, 674
- carcinoïd tumour 654, 665
- cytogenetic analysis 656, 657
- cytokeratin 7 (CK7), cytokeratin 20 (CK20) and other markers 651, 657
- diagnosis 645–646, 647–650, 651
- Ewing's sarcoma 448, 652, 656, 657, 658, 672
- flow cytometric immunophenotyping 656
- haemangiomyphangioma 668, 673
- haematological features 646–675
- histopathological features 646–675
- immunocytochemistry 656, 657
- immunohistochemistry 668–675
- Kaposi's sarcoma 666, 667, 668
- kidney carcinoma 653
- lung carcinoma 656, 662–665, 664
- malignant cells of non-haemopoietic origin 679–680
- malignant melanoma 653, 665, 666, 673
- markers 651
- molecular genetic analysis 656, 657
- neuroblastoma 654, 657, 666, 671, 675, 676, 677
- osteosclerosis 692–693
- peripheral blood 646
- prostate carcinoma 652, 659, 660–662, 660, 663
- rhabdomyosarcoma 655, 657, 666–668, 672
- small cell carcinoma 655–656, 662, 664, 673, 677
- tumour infiltration of bone marrow, identifying 678–680
- microarray analysis, molecular genetic analysis 101
- microorganisms, bone marrow culture, diagnostic technique 106
- minimal differentiation, acute myeloid leukaemia (AML) with 213–214
- mitochondrial cytopathies, including Pearson syndrome 610
- molecular genetic analysis 91–104
 acute myeloid leukaemia (AML) 190, 212–213
- blastic plasmacytoid dendritic cell neoplasm 228–229
- clonal immunoglobulin rearrangements 102–103
- diagnostic techniques 91–104
- fluorescence *in situ* hybridization (FISH) 91–97
- leukaemia investigation 102
- leukaemia/lymphoma-associated fusion genes 103–104
- lymphoma investigation 102
- microarray analysis 101
- next-generation sequencing (NGS) 101
- other techniques 101–102
- polymerase chain reaction (PCR) 97–101
- reverse transcriptase polymerase chain reaction (RT-PCR) 99–101
- in situ* hybridization (ISH) 91–97
- Southern blot analysis 97
- T-cell receptor gene rearrangements 102–103
- therapy-related myeloid neoplasms 212–213
- monoclonal antibodies
 acute myeloid leukaemia (AML) 188, 190
- flow cytometric immunophenotyping 75, 76
- monoclonal B-cell lymphocytosis 367

monoclonal gammopathies 517–518
 monocytopoiesis 21–22
 cytology 21
 histology 21–22
 morphometry of bone 685
 MPN *see* myeloproliferative neoplasms
 MSB (Martius scarlet blue) **70**
 mucopolysaccharidoses 632–633
 bone marrow cytology 632, 633
 bone marrow histology 633
 peripheral blood 632
 mu heavy chain disease 525
 bone marrow cytology 525
 peripheral blood 525
 multiple myeloma *see* plasma cell myeloma
 mustard gas, haematological effects 599
 mycosis fungoides 434
 bone marrow cytology 434
 bone marrow histology 434
 flow cytometric
 immunophenotyping 434
 peripheral blood 434
 myelodysplasia-related changes,
 acute myeloid leukaemia (AML) 208–211
 myelodysplastic/myeloproliferative neoplasm, unclassifiable 329
 myelodysplastic/myeloproliferative neoplasms 317–329
 atypical chronic myeloid leukaemia, *BCR-ABL1* negative 320–324
 chronic myelomonocytic leukaemia (CMML) 317–320
 juvenile myelomonocytic leukaemia (JMML) 324–327
 myelodysplastic/myeloproliferative neoplasm, unclassifiable 329
 myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)/refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) 327–329
 refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T)/myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) 327–329

myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)/refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) 327–329
 bone marrow cytology 327
 bone marrow histology 327, 329
 clinical features 327
 cytogenetic analysis 327–328
 diagnostic criteria 328
 molecular genetic analysis 327–328
 peripheral blood 327, 328
 problems and pitfalls 329
 myelodysplastic syndrome,
 unclassifiable 250
 myelodysplastic syndromes (MDS) 85, 86, 185, 230–253
 bone marrow cytology 234–235
 bone marrow histology 237–240
 clinical features 231
 cytochemistry 235–236
 cytogenetic analysis 242, **243**
 diagnosis 231
 FAB (French–American–British) classification **232**
 flow cytometric
 immunophenotyping 240
 immunohistochemistry 240–242
 incidence 230–231
 International Prognostic Scoring System (IPSS-R) 242, **243**
 molecular genetic analysis 242
 peripheral blood 232–234
 problems and pitfalls 251–253, 254
 prognosis 242–243
 WHO (World Health Organization) classification **233**, 243–253
 myelodysplastic syndrome with excess blasts (MDS-EB) 247–249
 bone marrow cytology 248
 bone marrow histology 248–249
 cytogenetic analysis 249
 peripheral blood 248
 myelodysplastic syndrome with isolated del(5q)
 ('5q- syndrome')
 bone marrow cytology 250
 bone marrow histology 250
 cytogenetic analysis 250
 diagnostic criteria 249
 molecular genetic analysis 250
 peripheral blood 250
 problems and pitfalls 250
 myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD) 245–246
 bone marrow cytology 245–246
 bone marrow histology 246
 cytogenetic analysis 246
 peripheral blood 246–247
 myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia (MDS-RS-SLD) 245–246
 bone marrow cytology 245–246
 bone marrow histology 246
 cytogenetic analysis 246
 peripheral blood 245
 myelodysplastic syndrome with single lineage dysplasia (MDS-SLD) 244–245
 bone marrow cytology 244–245
 bone marrow histology 245
 cytogenetic analysis 245
 diagnosis 244
 peripheral blood 244
 myeloid leukaemia associated with Down syndrome, acute myeloid leukaemia (AML) 221–222
 myeloid/lymphoid neoplasms with *FGFR1* rearrangement 333–334
 bone marrow cytology 333, 334
 bone marrow histology 333, 334
 cytogenetic analysis 333–334
 molecular genetic analysis 333–334
 peripheral blood 333
 myeloid/lymphoid neoplasms with *PCM1-JAK2* 334–335
 bone marrow cytology 334, 335
 bone marrow histology 334, 335
 clinical features 334
 cytogenetic analysis 335
 molecular genetic analysis 335
 peripheral blood 334–335
 myeloid/lymphoid neoplasms with *PDGFRA* rearrangement 330–332
 bone marrow cytology 330, 331
 bone marrow histology 330–331, 331
 cytogenetic analysis 332
 molecular genetic analysis 332
 peripheral blood 330, 331
 problems and pitfalls 332

- myeloid/lymphoid neoplasms with *PDGFRB* rearrangement 332–333
bone marrow cytology 332, 333
bone marrow histology 332–333
cytogenetic analysis 333
molecular genetic analysis 333
peripheral blood 332
problems and pitfalls 333
myeloid/lymphoid neoplasms with rearrangement of *PDGFRA*, *PDGFRB* or *FGFR1*, or with *PCM1-JAK2* 329–335
myeloid/lymphoid neoplasms with *FGFR1* rearrangement 333–334
myeloid/lymphoid neoplasms with *PCM1-JAK2* 334–335
myeloid/lymphoid neoplasms with *PDGFRA* rearrangement 330–332
myeloid/lymphoid neoplasms with *PDGFRB* rearrangement 332–333
myeloid proliferations related to Down syndrome, acute myeloid leukaemia (AML) 220–222
myeloproliferative neoplasm, unclassifiable 316–317
WHO (World Health Organization) classification 317
myeloproliferative neoplasms (MPN) 267–317
chronic eosinophilic leukaemia (CEL), not otherwise specified 299–302
chronic myeloid leukaemia (CML), *BCR-ABL1+* (chronic myelogenous leukaemia, chronic granulocytic leukaemia) 268–277
chronic neutrophilic leukaemia 277–279
classification 267–268
diagnosis 267–268
essential thrombocythaemia (ET) 284–291
myeloproliferative neoplasm, unclassifiable 316–317
polycythaemia vera (PV) 279–284
primary myelofibrosis (PMF) 291–299
systemic mastocytosis 302–315
WHO (World Health Organization) classification 268
- natural killer (NK) lineage disorders
see lymphoproliferative disorders of T lineage and natural killer (NK) lineage
necrosis, bone necrosis (osteonecrosis) and repair 693
necrosis, bone marrow *see* bone marrow necrosis
needle biopsy *see* trephine biopsy
neonates, cellularity 11–12
neuroblastoma 654, 657, 666, 671, 675, 676, 677
neutropenia
see also leucocytes disorders
drug-induced 566–567
next-generation sequencing (NGS), molecular genetic analysis 101
Niemann–Pick disease 625–626
bone marrow cytology 625
bone marrow histology 626
peripheral blood 625
nitrous oxide, haematological effects 597
NK (natural killer) lineage disorders
see lymphoproliferative disorders of T lineage and natural killer (NK) lineage
NK-lymphoblastic leukaemia/lymphoma 421
nodal marginal zone B-cell lymphoma 398–399
bone marrow histology 399
cytogenetic analysis 399
flow cytometric immunophenotyping 399
immunohistochemistry 399
molecular genetic analysis 399
peripheral blood 399
problems and pitfalls 399
nodular lymphocyte-predominant Hodgkin lymphoma 459–460
bone marrow cytology 460
bone marrow histology 460
cytogenetic analysis 460
flow cytometric immunophenotyping 460
immunohistochemistry 460
molecular genetic analysis 460
peripheral blood 460
problems and pitfalls 460
non-haemopoietic cells, antigens expressed for demonstration of metastatic tumours 647–650
non-haemopoietic tumours 656, 668
non-Hodgkin lymphoma, HIV/AIDS 162
- non-IgM monoclonal gammopathy of undetermined significance 511–514
bone marrow cytology 513
bone marrow histology 513
classification 511–513
cytogenetic analysis 513
diagnosis 512
flow cytometric immunophenotyping 513
immunohistochemistry 513
molecular genetic analysis 513
peripheral blood 513
problems and pitfalls 513–514
WHO (World Health Organization) classification 511–513
non-metastatic effects of cancer 585, 586
bone marrow cytology 585
bone marrow histology 585
peripheral blood 585
NPM1 mutation, acute myeloid leukaemia (AML) 207–208
- osteoblasts 29–33
cytology 31, 32
histology 32, 33, 34
osteoclasts 29–33
cytology 31, 32
histology 32, 33, 34
osteogenesis imperfecta 695
osteomalacia 687
causes 687
definition 687
osteonecrosis (bone necrosis) and repair 693
osteopetrosis (Albers–Schoenberg disease) 693–695
osteoporosis 685–686
definition 685
histology 686
measurement of bone mass 686
mechanism 686
osteosclerosis 692–693
associated conditions 692
metastatic tumours 692–693
other syndromes associated with secretion of a paraprotein 518–529
oxalosis 630–631, 632
bone marrow biopsy 631, 632
peripheral blood 630
- Paget's disease of bone 690–692
paraffin embedding, trephine biopsy 700–705, 706–707

parasitic diseases
 bone marrow cytology 132–134
 bone marrow histology 134–136
 peripheral blood 131–132
 problems and pitfalls 136
 paratrabecular fibrosis 309
 adult T-cell leukaemia/lymphoma (ATLL) 441
 hyperparathyroidism 688
 POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome 526
 paroxysmal nocturnal haemoglobinuria (PNH) 611–614
 bone marrow cytology 613, 614
 bone marrow histology 613–614
 causes 612
 evolution 612–613
 immunohistochemistry 613–614
 peripheral blood 613
 parvovirus B19: 125
 diagnosis 124
 PAS *see* periodic acid–Schiff staining
 PCR (polymerase chain reaction) 97–101
 Pearson syndrome and other mitochondrial cytopathies 610, 611
 bone marrow cytology 610, 611
 peripheral blood 610, 611
 Pelger–Huët anomaly 566, 567, 593
 bone marrow cytology 566, 567
 peripheral blood 566, 593
 penicillamine, haematological effects 599
 periodic acid–Schiff (PAS) staining 70
 HIV/AIDS 115
 trephine biopsy 704
 Whipple's disease 110–111
 peripheral T-cell lymphoma, not otherwise specified 450–453
 bone marrow cytology 450, 451
 bone marrow histology 451–452
 cytogenetic analysis 451
 flow cytometric immunophenotyping 451
 immunohistochemistry 451, 452
 molecular genetic analysis 451, 452
 peripheral blood 450
 problems and pitfalls 453
 Perls' stain for haemosiderin 36, 61–63, 65–67
 trephine biopsy 704–705

plasmablastic lymphoma 413
 plasma cell leukaemia 509–511
 bone marrow cytology 510
 bone marrow histology 510, 511
 cytogenetic analysis 510–511
 flow cytometric immunophenotyping 510
 molecular genetic analysis 510–511
 peripheral blood 510, 511
 plasma cell myeloma (multiple myeloma) 487–509
 bone marrow cytology 489–494
 bone marrow histology 494–502
 clinical features 487
 cytogenetic analysis 503–504
 diagnosis 487–488, 493–494
 flow cytometric immunophenotyping 494
 HIV/AIDS 506, 508
 immunohistochemistry 502–503
 incidence 487
 molecular genetic analysis 503–504
 peripheral blood 488, 505
 problems and pitfalls 504–509
 WHO (World Health Organization) classification 487–488
 plasma cell neoplasms 487–529
 acquired angio-oedema associated with plasma cell neoplasia 528–529
 alpha heavy chain disease 524
 chronic cold haemagglutinin disease (CHAD) 524
 essential and other paraprotein-associated cryoglobulinaemia 522–524
 gamma heavy chain disease 524–525
 IgM monoclonal gammopathy of undetermined significance (IgM MGUS) 514
 light chain and heavy chain deposition diseases 521–522
 light chain-associated amyloidosis 517–521
 mu heavy chain disease 525
 non-IgM monoclonal gammopathy of undetermined significance 511–514
 other syndromes associated with secretion of a paraprotein 517–529
 plasma cell leukaemia 509–511
 plasma cell myeloma (multiple myeloma) 487–509
 POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome 525–527, 528
 TEMPI syndrome 527
 Waldenström macroglobulinaemia 514–517
 plasma cells, lymphopoiesis 35–36
 plasmacytosis
 bone marrow cytology 147–148
 bone marrow histology 148–149
 infection and reactive changes 147–149
 peripheral blood 147
 platelet disorders 573–578
 acquired thrombocytopenia 575–578
 congenital thrombocytopenias 573–575
 familial thrombocytosis 576–578
 reactive thrombocytosis 577–578
 PMF *see* primary myelofibrosis
 PNH *see* paroxysmal nocturnal haemoglobinuria
 POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome 525–527, 527–528
 bone marrow cytology 525–527
 bone marrow histology 525–527
 peripheral blood 525
 polyclonal antibodies, acute myeloid leukaemia (AML) 190
 polycythaemia 563
 polycythaemia vera (PV) 279–284
 bone marrow cytology 281
 bone marrow histology 281–282, 283
 'burnt out' or 'spent' phase 280
 cytogenetic analysis 282–284
 molecular genetic analysis 282–284
 peripheral blood 280
 problems and pitfalls 284
 WHO (World Health Organization) classification 280, 281
 polymerase chain reaction (PCR) 97–101
 polymorphous lymphoid hyperplasia 145–147
 post-transplant and other immunodeficiency-associated lymphoproliferative disorders and their relationship to the Epstein–Barr virus 460–464
 classification 461–464
 WHO (World Health Organization) classification 463–464

- primary cutaneous follicle centre cell lymphoma, follicular lymphoma 387
- primary cutaneous gamma-delta T-cell lymphoma 434
- primary diffuse large B-cell lymphoma of the CNS 408
- primary effusion lymphoma 411–413
- primary mediastinal (thymic) large B-cell lymphoma 408
- primary myelofibrosis (PMF) 291–299
- bone marrow cytology 293–294
 - bone marrow histology 294–297
 - cytogenetic analysis 297–299
 - molecular genetic analysis 297–299
 - peripheral blood 291–293
 - problems and pitfalls 299
 - WHO (World Health Organization) classification 291, **292**
- prostate carcinoma 652, 659, 660–662, 660, 663
- protein-calorie malnutrition and calorie deficiency 621–622
- bone marrow cytology 621–622
 - peripheral blood 621
- protozoal pathogens, differential diagnosis **131**
- pseudo-Gaucher cells 623–625
- problems and pitfalls 623–625
- pure erythroid leukaemia, acute
- myeloid leukaemia (AML) 217–218, **219**
- pure red cell aplasia (including Blackfan–Diamond syndrome) 558–563
- bone marrow cytology 560, 561
 - bone marrow histology 560–562, 563
 - causes 559
 - peripheral blood 560
 - problems and pitfalls 562–563
- PV *see* polycythaemia vera
- radiotherapy effect *see* irradiation effect on bone marrow
- RARS (refractory anaemia with ring sideroblasts) 245–246
- RARS-T *see* refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T)/myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
- RCMD (refractory cytopenia with multilineage dysplasia) 246–247
- RCUD (refractory cytopenia with unilineage dysplasia (RCUD) 244–245
- reactive lymphoid aggregates
- bone marrow cytology 145
 - bone marrow histology 145–147
 - peripheral blood 145
 - problems and pitfalls 147
- reactive thrombocytosis 577–578
- bone marrow cytology 578
 - bone marrow histology 578
 - peripheral blood 578
 - problems and pitfalls 578
- recombinant human growth factors, haematological effects 576–577, 597
- red cells disorders 537–563
- anaemia of chronic disease 555–556
 - Blackfan–Diamond syndrome 558–563
 - congenital dyserythropoietic anaemias (CDA) 547–551
 - haemoglobin H disease 544
 - haemolytic anaemias 544–547
 - iron deficiency anaemia 537–539
 - megaloblastic anaemia 551–555
 - polycythaemia 563
 - pure red cell aplasia (including Blackfan–Diamond syndrome) 558–563
 - sickle cell disease 556–558
 - sideroblastic anaemia 539–541
 - thalassaemia major 542–544
 - thalassaemia trait and thalassaemia intermedia 541–542
- refractory anaemia with excess of blasts (RAEB) 247–249
- refractory anaemia with ring sideroblasts (RARS) 245–246
- refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T)/myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) 327–329
- refractory cytopenia of childhood
- bone marrow cytology 251
 - bone marrow histology 251
 - cytogenetic analysis 251
 - diagnostic criteria 250
 - peripheral blood 251
- refractory cytopenia with multilineage dysplasia (RCMD) 246–247
- diagnostic criteria 250
- refractory cytopenia with unilineage dysplasia (RCUD) 244–245
- renal osteodystrophy 688–690
- resin embedding, trephine biopsy 701, 705–706
- reticulin fibrosis 160, 162, 168–170
- reticulin staining 67–70, 702–705
- reverse transcriptase polymerase chain reaction (RT-PCR) 99–101
- rhabdomyosarcoma 655, **657**, 666–668, 672
- rickettsial and bacterial infection *see* bacterial and rickettsial infection
- rifampicin, haematological effects 597
- Rosai–Dorfman disease (sinus histiocytosis with massive lymphadenopathy) 633
- RT-PCR (reverse transcriptase polymerase chain reaction) 99–101
- RUNX1* mutation, acute myeloid leukaemia (AML) 208
- Sanfilippo syndrome 633
- sea-blue histiocytes 628–629
- bone marrow cytology 628
 - bone marrow histology 628
 - causes 628–629
- secondary myelodysplasia 586–590
- bone marrow cytology 587, 589–590
 - bone marrow histology 587–588
 - dyserythropoiesis 587, 589–590
 - peripheral blood 587
 - problems and pitfalls 588–590
- serous degeneration/atrophy 166–167
- Sézary syndrome 431–433
- bone marrow cytology 432
 - bone marrow histology 433
 - cytogenetic analysis 432, 433
 - flow cytometric immunophenotyping 432–433
 - immunohistochemistry 432, 433
 - molecular genetic analysis 432, 433
 - peripheral blood 432
 - problems and pitfalls 433
 - ultrastructural examination 104
- short-term haemopoietic cultures 104–105
- Shwachman–Diamond syndrome 564
- sickle cell disease 556–558
- bone marrow cytology 556–557
 - bone marrow histology 557, 558

- peripheral blood 556
problems and pitfalls 557–558
- sideroblastic anaemia
bone marrow cytology 540–541
bone marrow histology 541
causes 539
peripheral blood 540
problems and pitfalls 541
- sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease) 602, 633
- SKY (spectral karyotyping) 95–96
- small cell carcinoma 655–656, 662, 664, 673, 677
- sodium aurothiomalate,
haematological effects 599
- Southern blot analysis, molecular genetic analysis 97
- spectral karyotyping (SKY) 95–96
- splenic B-cell lymphoma/leukaemia, unclassifiable 399–401
hairy cell leukaemia
variant 400–401
- splenic diffuse red pulp small B-cell lymphoma 399–400
- splenic diffuse red pulp small B-cell lymphoma
bone marrow cytology 399
cytogenetic analysis 399–400
flow cytometric
immunophenotyping 399
molecular genetic analysis 399–400
peripheral blood 399
problems and pitfalls 400
- splenic marginal zone lymphoma (SMZL) 393–398
bone marrow cytology 395–396
bone marrow histology 397, 398
cytogenetic analysis 396–397
flow cytometric
immunophenotyping 396
immunohistochemistry 396, 398
molecular genetic analysis 396–397
peripheral blood 394–395
problems and pitfalls 398
- splenomegaly, essential
thrombocythaemia (ET) 285
- stem cell transplantation 614–617
bone marrow cytology 615–616
bone marrow histology 616
donor-lymphocyte infusion 617
graft-versus-host disease (GVHD) 614–617
peripheral blood 615
problems and pitfalls 616–617
- storage diseases and storage cells in the bone marrow 622–635, 636–637
- crystal-containing macrophages in myeloid leukaemias 629
- crystal-storing histiocytosis 624–625
- cystinosis 629–630, 631
- foamy macrophages 626–628
- foreign substances deposition 633–634
- Gaucher's disease 622–623
- glycogen storage disease 633
- gout 633
- hyperoxaluria 630–631, 632
- macrophages containing cholesterol crystals 628
- mucopolysaccharidoses 632–633
- Niemann–Pick disease 625–626
- oxalosis 630–631, 632
- pseudo-Gaucher cells 623–625
- Rosai–Dorfman disease (sinus histiocytosis with massive lymphadenopathy) 633
- sea-blue histiocytosis 628–629
- sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease) 633
- vascular and intravascular lesions 634–635, 636–637
- streptavidin–biotin–peroxidase method, trephine biopsy 706–707
- stromal dendritic cells 22–24
cytology 23
histology 23
immunohistochemistry 23–24
- subcutaneous panniculitis-like T-cell lymphoma 434
- systemic mastocytosis 302–315
bone marrow cytology 305–307
bone marrow histology 307–311
cytogenetic analysis 312–314
flow cytometric
immunophenotyping 311–312
molecular genetic analysis 312–314
- peripheral blood 304–305
problems and pitfalls 314–315
- WHO (World Health Organization) classification 303, 304
- t(1;22)(p13.3;q13.1); *RBM15-MKL1*, acute myeloid leukaemia (AML) 205–206
- t(6;9)(p23;q34.1); *DEK-NUP214*, acute myeloid leukaemia (AML) 204
- t(8;21)(q22;q22.1); *RUNX1-RUNX1T1*, acute myeloid leukaemia (AML) 197–198
- t(9;11)(p21.3;q23.3); *KMT2A-MLLT3*, acute myeloid leukaemia (AML) 203
- t(9;22)(q34.1;q11.2); *BCR-ABL1*, acute myeloid leukaemia (AML) 206–207
- t(15;17)(q22;q11-12); *PML-RARA*, acute myeloid leukaemia (AML) 200–203
- T-cell and NK-cell neoplasms, WHO (World Health Organization) classification 348
- T-cell/histiocyte-rich large B-cell lymphoma 407–408
- bone marrow histology 407–408
immunohistochemistry 408, 409, 410
problems and pitfalls 408
- T-cell large granular lymphocytic leukaemia 424–427
- bone marrow cytology 425
- bone marrow histology 425–426, 427
- cytogenetic analysis 425
- flow cytometric
immunophenotyping 425
- immunohistochemistry 425, 426
- molecular genetic analysis 425
- peripheral blood 424
- problems and pitfalls 426–427
- T-cell prolymphocytic leukaemia 422–424
- bone marrow cytology 422
- bone marrow histology 423
- cytogenetic analysis 423
- flow cytometric
immunophenotyping 422, 423
- immunohistochemistry 423
- molecular genetic analysis 423
- peripheral blood 422
- problems and pitfalls 424
- T-cell receptor gene rearrangements, molecular genetic analysis 102–103
- TEMPI syndrome 527
- thalassaemia major 542–544
bone marrow cytology 543
bone marrow histology 544
peripheral blood 543
- thalassaemia trait and thalassaemia intermedia 541–542
bone marrow cytology 542
bone marrow histology 542
diagnosis 541–542

- thalassaemia trait and thalassaemia intermedia (*cont'd*)
 peripheral blood 542
 problems and pitfalls 542
- therapy-related myeloid neoplasms
 acute myeloid leukaemia (AML)
 211–213
 bone marrow cytology 212
 bone marrow histology 212
 cytochemistry 212
 cytogenetic analysis 212–213
 immunophenotype 212
 molecular genetic analysis 212–213
 peripheral blood 212
- thrombocytopenias 119
see also acquired thrombocytopenias; congenital thrombocytopenias
- thrombocytosis, essential
 thrombocythaemia (ET)
 284–285
- thrombopoiesis 24–28
- thyroid disease 693
- T lineage and natural killer (NK)
 lineage, lymphoproliferative disorders of *see*
 lymphoproliferative disorders of T lineage and natural killer (NK) lineage
- T-lymphoblastic leukaemia/
 lymphoma 419–421
 bone marrow cytology 420
 bone marrow histology 421
 cytogenetic analysis 420, 421
 flow cytometric
 immunophenotyping 420–421
 immunohistochemistry 420, 421
 molecular genetic analysis
 420, 421
 peripheral blood 419
 problems and pitfalls 421
- toluidine blue 70
- Toxoplasma gondii* 131, 135, 136
- transient abnormal myelopoiesis,
 acute myeloid leukaemia (AML)
 220–221, 222, 224
- trepentine biopsy 7–10, 13, 23, 24
 aceto-zinc fixative method 701
 adaption of methods in a resource-poor setting 708
 artefacts 45–57
 audit 45
 decalcification 700, 701
 diagnostic technique 65–71
 examination, bone marrow 7–10,
 13, 23, 24, 43–45
 fixation 699–700, 701
- Giemsa staining for paraffin-embedded sections 702
- Giemsa staining for resin-embedded sections 705–706
- glycol methacrylate (resin embedding) 701
- Gomori's method for reticulin staining 703–704
- Gordon and Sweet's technique for reticulin staining 702–703
- guidelines 45
- haematoxylin and eosin (H&E) for paraffin-embedded sections 702
- haematoxylin and eosin (H&E) for resin-embedded sections 705
- histochemical staining 65–71
- histochemical staining for paraffin-embedded sections 701–705, 706–707
- histochemical staining for resin-embedded sections 705–706
- histochemical stains 65–71
- immunohistochemical staining of paraffin-embedded sections (which have been fixed in 10% neutral buffered formal saline) 706–707
- immunohistochemistry 85–88
- interpretation 43–45
- paraffin embedding 700–705,
 706–707
- periodic acid-Schiff (PAS) staining 704
- Perls' stain for haemosiderin 704–705
- processing 700–701
- reports 45
- resin embedding 701, 705–706
- reticulin staining 702–703
- reticulin staining for resin-embedded sections 705
- streptavidin-biotin-peroxidase method 706–707
- technical methods 699–708
- trientine, haematological effects 599
- tumours, metastatic *see* metastatic tumours
- ultrastructural examination 104
 diagnostic technique 104
- valproic acid, haematological effects 597
- 'vanishing bone disease' 695
- vascular and intravascular lesions 634–635
- bone marrow cytology 634
- bone marrow histology 634–635,
 636–637
- peripheral blood 634
- viral infections
see also specific viral infections
- bone marrow cytology 118–119
- bone marrow histology 119–125
- diagnosis 124–126
- infection and reactive changes 116–126
- peripheral blood 116–118
- problems and pitfalls 125–126
- Waldenström macroglobulinaemia 514–517
- bone marrow cytology 515
- bone marrow histology 515–516, 517
- cytogenetic analysis 517
- immunohistochemistry 516–517
- molecular genetic analysis 517
- peripheral blood 514
- Whipple's disease 110–111, 113
- WHO (World Health Organization) classification
 acute myeloid leukaemia (AML)
 186, 188, 196–230
 atypical chronic myeloid leukaemia, *BCR-ABL1* negative 322
 B-lineage lymphomas and leukaemias 347
 chronic eosinophilic leukaemia, not otherwise specified 300
 chronic myeloid leukaemia, *BCR-ABL1+* (chronic myelogenous leukaemia, chronic granulocytic leukaemia) 269
 chronic myelomonocytic leukaemia (CMML) 318
 essential thrombocythaemia (ET) 285
 Hodgkin lymphoma 348
 juvenile myelomonocytic leukaemia (JMML) 325
 light chain and heavy chain deposition diseases 522
 light chain-associated amyloidosis 518
 lymphoproliferative disorders of T lineage and natural killer (NK) lineage 418–419
 mastocytosis 303, 304
 myelodysplastic syndromes (MDS) 233, 243–253
 myeloproliferative neoplasm, unclassifiable 317

myeloproliferative neoplasms
(MPN) **268**
non-IgM monoclonal gammopathy
of undetermined significance
511–513
plasma cell myeloma (multiple
myeloma) **487–488**
polycythaemia vera (PV)
280, 281

post-transplant and other
immunodeficiency-associated
lymphoproliferative disorders
and their relationship to the
Epstein–Barr virus **463–464**
primary myelofibrosis **291, 292**
T-cell and NK-cell neoplasms **348**
Wilson's disease, haematological
effects **599, 600**

Wiskott–Aldrich syndrome **327, 592**
congenital thrombocytopenia
573, 574
Zenker's fixative **70–71, 699**
Ziehl–Neelsen (ZN) stain **70**
Zieve's syndrome **602, 603, 627**
zinc toxicity, haematological
effects **599**

